Back

Incidence and prognosis of cardiotoxicity in a group of breast cancer patients under treatment with anti-HER2 drugs

29 June 2021 (08:00 - 23:59)
Organised by:
Congress Presentation Part of: ePoster session Cardiotoxicity of Drugs and Other Therapies HFA Premium Access Heart Failure 2021

About the speaker

Photo
Doctor Patricia Azanon Cantero

Virgen de las Nieves University Hospital, Granada (Spain)

738 More presentations in this session

Presentation thumbnail
Atrial lead insertion during cardiac implantable electronic devices implantation in patients with atrial arrhythmia on hospital admission, when does the struggle for sinus rhythm make sense?
Assistant Professor N. Radovanovic (Belgrade, RS)
Abstract Slides
Presentation thumbnail
Features of the remodeling of atria and pulmonary veins in CHF patients with paroxysmal AF and permanent AF
Assistant Professor V. Kirillova (Ekaterinburg, RU)
Abstract Slides
Presentation thumbnail
Rhythm control versus rate control in patients with atrial fibrillation and heart failure across the left ventricular ejection fraction spectrum
Doctor D. Moysidis (Zurich, CH)
Abstract Slides
Presentation thumbnail
Impact of cardiac contractility modulation on ventricular rhythm and conduction disorders in patients with heart failure with reduced ejection fraction and various forms of atrial fibrillation
Doctor A. Safiullina (Moscow, RU)
Abstract Slides
Presentation thumbnail
Was a difference between late and early new-onset of atrial fibrillation in non st-elevation myocardial infarction?
Doctor H. Santos (Lisboa, PT)
Abstract Slides

Access the full session

Session thumbnail
ePoster session

The Event

Event poster

Heart Failure 2021

29 June 2021 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Cardiovascular toxicity surveillance in metastatic breast cancer patients receiving long-term HER2-targeted therapy: a retrospective multicentre study
thumbnail
Congress Presentation
HEARTOX-P: a novel multiparametric score for predicting cardiotoxicity in HER2-positive breast cancer patients undergoing chemotherapy
thumbnail
Congress Presentation
Cardiovascular toxicity prediction in breast cancer patients: the HFA/ICOS risk tool in real-world practice

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources